Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: October 16, 2008
Event: Completion of the sale of Abbott's spine business to Zimmer, Inc.
Key Financial Metrics
- Sale Proceeds: Approximately $360 million in cash.
- Expected Gain: One-time pretax gain of at least $150 million.
- Accounting Treatment: The gain will be treated as a specified item in the fourth quarter of 2008.
Note: This filing does not provide data on overall revenue, profit, cash flow, margins, debt, or liquidity for the company as a whole.
Material Changes
The primary material change is the divestiture of the spine business unit. This transaction results in an immediate cash inflow and a significant one-time pretax gain, altering the company's asset base and fourth-quarter earnings profile.
Guidance, Outlook, and Risks
Management Commentary: Abbott intends to classify the transaction gain as a specified item for Q4 2008 reporting.
Risks and Uncertainties: The filing includes a caution regarding forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to economic, competitive, governmental, and technological factors. Detailed risk factors are referenced in the company's 2007 Form 10-K and the June 30, 2008 Form 10-Q.
Investor Verification Checklist
- Verify the final closing date and exact cash proceeds received from Zimmer, Inc.
- Confirm the precise calculation of the $150 million pretax gain in the Q4 2008 earnings release.
- Review the impact of this divestiture on future revenue streams and operating expenses related to the spine business.
- Check subsequent filings for any revisions to the "specified item" classification or tax implications of the gain.